Re: Epigenetics market size
in response to
by
posted on
Jan 25, 2024 11:48AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Very helpful post nbb.
As you pointed out 25 named but no RVX or ZCC? Where are RVX and ZCC? No profile after 21 years in the business.
There are 2 sides to this equation:
From what I recall RVX and ZCC have approximately 4,000 molecules in their closet with only 2 in test (actually just 1 now). Don has stated many of times over my 14 years of involvement that there is an opportunity to license out some of the molecules to generate revenue but of course nothin had happened...not a penny generated.
Epigenetic Major Players Globe Newswire Jan 24 2024
Epigenetics market major players covered in the report, such as:
· Thermo Fisher Scientific Inc (US)
· Merck KGaA (Germany)
· Illumina, Inc. (US)
· PacBio (US)
· Abcam plc (UK)
· Active Motif, Inc. (US)
· Bio-Rad Laboratories Inc. (US)
· Promega Corporation (US)
· Revvity (US)
· Qiagen (Germany)
· New England Biolabs (US)
· Zymo Research Corporation (US)
· Diagenode SA (US)
· F. Hoffmann-La Roche Ltd (Switzerland)
· EpiGentek Group Inc. (US)
· EpiCypher (US)
· Fios Genomics (UK)
· GenomeScan (Netherlands)
· Creative Biogene (US)
· BPS Bioscience Inc. (US)
· Abnova Corporation (Taiwan)
· Creative Diagnostics (US)
· biomodal (UK)
· Integrated DNA Technologies Inc. (US)
· Novogene Co. Ltd (China)
· and Among Others
Final comment is this is an evolving, complex space with lots of potential but it will require big $$$ to compete.
GLTA
Toinv